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bust to changes of most parameters—most sensitive to
prevalence and eradication efficacy changes.
PGI10
IRRITABLE BOWEL SYNDROME COSTS 
SICKNESS FUNDS DM 2.8 BILLION PER YEAR
Schultes HJ1, Guminski W2, Rosche U2, Ries B1, Pirk O3
1Novartis Pharma, Nuremberg, Germany; 2IG 
Gesundheitsforschung, Munich, Germany; 3Fricke & Pirk, 
Nuremberg, Germany
BACKGROUND: With a prevalence of up to 20%, Irri-
table Bowel Syndrome (IBS) could cost the German Sick-
ness Funds (GKV) more than DM 28 billion (10,5% of
its total expenditures) per year. Despite these potentially
tremendous costs it is still a fairly obscure disease in
terms of proper diagnosis and lacking effective treatment.
OBJECTIVE: To assess diagnosis and treatment options
of IBS using strict Rome-II criteria. METHODS: Face-to-
face interviews of patients (121) and physicians (147
GPs, 53 internists). RESULTS: The patient survey (age
14–74 yrs.; strict Rome-II criteria) puts the prevalence of
IBS (constipated and alternating type) in Germany at
around 2.3% (1.4 million). This figure correlates well
with previous findings. The patients responded that they
experienced an average of 7 episodes per year, each last-
ing about 4–5 days. Some 11% of them suffer perma-
nently. Of the physicians questioned, only 73% recognize
IBS when given the symptoms; 57% of these actually
classify it accordingly while an alternative diagnosis is
“irritable colon” (24%). When choosing a drug, daily
treatment costs outweigh every other factor of the physi-
cians relevant set (efficacy, onset, side-effects, mode of
action etc.) by about 3:1. In consequence a drug treat-
ment is initiated in (only) 40% of the cases. This is also
due to a lack of effective and specific treatment which
could help to reduce the frequency of episodes. Results of
another study put the direct costs of the average IBS pa-
tient at around DM 1,729 per year. Combining this with
the above findings results in a more realistic figure of
around DM 988 million in direct costs per year (0.37%
of total GKV expenditures). CONCLUSION: These com-
parably high costs (insulin treated diabetes: DM 1,217
p.a.) could be significantly reduced by DM 247 for each
episode prevented through proper diagnosis and conse-
quent treatment with a specific and effective medication.
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OBJECTIVES: The objective was to describe the disease
state (DS) transition patterns of gastroesophageal reflux
disease (GERD) by applying a multi-state model assum-
ing a Markov process. METHODS: This retrospective
study utilized administrative claims for subjects with
GERD from a large Midwest USA health care plan. Sub-
jects were tracked for six, six-month time periods (base-
line and five followups). Within each time period, ICD-9
diagnosis codes were used to categorize subjects’ GERD
into four DS plus a non-symptomatic state: DS0 {no
GERD diagnosis}, DS1 {mild esophagitis}, DS2 {reflux
esophagitis}, DS3 {esophageal ulceration}, and DS4 {stric-
tures and complications}. GERD transition probabilities
and patterns were analyzed in a five-state Markov frame-
work. Disease regressions and progressions were al-
lowed. The effects of patient and provider covariables on
transition probabilities were modeled using logistic re-
gression techniques. RESULTS: A total of 7575 subjects
with GERD were analyzed. In the five followup periods
combined, 79% of the subjects were in GERD DS0, 6%
in DS1, 8% in DS2, 2% in DS3, and 5% in DS4. For all
initial DS, the most frequent transition path was to re-
gress to DS0 (becoming non-symptomatic) and the sec-
ond most common was to stay in the initial disease state.
For subjects ending a time period in DS1, 89% regressed
to DS0 in the next time period, while 6% stayed in DS1,
3% progressed to DS2, 1% progressed to DS3, and 1%
progressed to DS4. Multivariate modeling of risk factors
influencing transitions showed that progressing from
DS1 is associated with age 70, a proton pump inhibitor
prescription, and absence of a diagnostic procedure.
CONCLUSIONS: The Markov analysis showed that sub-
jects with GERD commonly have their symptoms regress,
with only a small percent progressing. The Markov
model is a useful methodology to research disease states
in a retrospective database setting within a health care
plan.
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OBJECTIVES: Approximately one-half of the American
population experiences weekly symptoms of gastroesoph-
ageal reflux disease (GERD). With the hypothesis that
not all patients are completely symptom free on proton
pump inhibitor’s (PPI’s), the pharmaceutical industry is
formulating more potent anti-secretory drug therapies. In
November of 2000 the FDA approved esomeprazole for
the treatment of Erosive Esophagitis (EE). Esomeprazole
is a more potent inhibitor of gastrin and gastric acid,
with clinical studies demonstrating quicker symptom re-
lief with more complete 24-hour acid control. If complete
acid control translates into better long-term symptom re-
lief for chronic symptomatic GERD it may play a vital
